By Fineline Cube Enginprime Medical announced the completion of its Series A funding round of nearly 100 million RMB, with Qiming Venture Partners participating as the sole investor. Proceeds will be directed primarily toward registration clinical trials for the company’s core product, OpusOne, in China, alongside overseas early‑stage clinical development.
Funding Milestone
| Item | Detail |
|---|---|
| Round | Series A |
| Size | ~100 million RMB |
| Investor | Qiming Venture Partners (sole) |
| Core Product | OpusOne (percutaneous ventricular assist device) |
| Announcement Date | 18 Aug 2026 |
| Use of Proceeds | Domestic registration trials for OpusOne; overseas early‑stage trial filings and execution |
Company & Product Profile
- Founded: 2023; high‑tech enterprise focused on R&D and commercial translation of innovative cardiovascular medical technologies.
- Focus Area: Percutaneous ventricular assist device (pVAD) sector — minimally invasive mechanical circulatory support for acute heart failure.
- Flagship Product: OpusOne, a next‑generation ventricular assist system.
- Design Philosophy: Small‑footprint, high‑flow architecture aimed at improving portability and clinical usability in critical care settings.
Use of Proceeds & Development Roadmap
- Domestic: Accelerate registration clinical trials for OpusOne in China, a key step toward NMPA regulatory approval.
- International: Fully support the filing and execution of early‑stage clinical trials overseas, signaling a global development pathway from an early stage.
Market Impact & Outlook
- Cardiovascular Device Landscape: China’s aging population and rising incidence of heart failure are expanding demand for advanced mechanical circulatory support, making pVAD a high‑growth device category.
- Differentiation: Enginprime’s emphasis on compact, high‑flow systems targets an unmet need for portable, catheter‑based cardiac support in intensive care workflows.
- Investor Signal: Qiming Venture Partners’ sole participation underscores continued institutional appetite for differentiated cardiovascular medtech in China.
- Strategic Positioning: With Series A capital secured, Enginprime is positioned to advance OpusOne through pivotal clinical and regulatory milestones in both domestic and international markets.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical trial timelines, regulatory filings, and commercialization expectations for OpusOne. Actual results may differ due to risks including trial outcomes, regulatory review, and competitive dynamics.-Fineline Info & Tech